Fisher & Paykel Healthcare Corporation Limited (FSPKF)
OTHER OTC:FSPKF
Earnings Data
Report Date
Dec 02, 2026After Close (Confirmed)
Period Ending
2027 (Q2)Consensus EPS Forecast
0.24Last Year’s EPS
0.21Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call conveyed a predominantly positive operational and financial performance: strong top-line growth, substantial NPAT expansion, margin improvement, robust cash flow, higher dividends and continued investment in capacity and R&D. The company provided constructive FY'27 guidance but also clearly articulated material near-term headwinds — notably U.S. tariffs, surcharges from the Middle East conflict, FX/hedging losses, and the risk of hardware growth normalizing after an exceptional year. Management stressed that continuous improvement and manufacturing/network flexibility should offset many of these pressures, but several macro and policy risks remain.Company Guidance
Strong Revenue Growth
Operating revenue of $2.3 billion, up 14% on prior year (12% in constant currency). FY'27 guidance: $2.45–$2.57 billion (approx. 6%–11% growth).
Material Net Profit Growth
Net profit after tax $468.5 million, up 24% on prior year (28% in constant currency). FY'27 NPAT guidance: $500–$550 million.
Hospital Segment Outperformance
Hospital operating revenue $1.5 billion, up 18% (15% constant currency). Hospital hardware revenue up ~27% in constant currency; new applications consumables up 18% (16% CC); Hospital consumables overall up 14% CC.
Homecare Growth and Product Momentum
Homecare revenue $802.7 million, up 8% (7% CC). OSA mask revenue up 7% (5% CC) driven by new Solo and Nova nasal/pillows ranges; Homecare hardware also showed growth.
Margin Expansion
Gross margin 63.7%, an increase of 122 basis points in constant currency versus prior year. Operating margin 27.6%, up 277 basis points in constant currency.
Strong Cash Generation
Operating cash flow $663 million, up 21% year-on-year. Net cash $401 million at 31 March 2026 and gearing of -22.8%.
Capital Investment for Capacity
Capital expenditure (including intangibles) $195 million (up from $103 million), including $132 million on a new building (East Tamaki) and payment on Karaka land; FY'27 capex guidance ~ $230 million.
Shareholder Returns Increased
Total dividends declared $0.52 per share, up 22% on prior year; final dividend $0.33 per share (65% payout of full year profit).
Fisher & Paykel Healthcare Corporation Limited (FSPKF) Earnings, Revenues Date & History
FSPKF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FSPKF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 25, 2025 | $20.43 | $20.43 | 0.00% |
May 27, 2025 | $20.40 | $20.40 | 0.00% |
Nov 27, 2024 | $21.28 | $22.13 | +3.99% |
May 27, 2024 | $16.66 | $15.97 | -4.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Fisher & Paykel Healthcare Corporation Limited (FSPKF) report earnings?
Fisher & Paykel Healthcare Corporation Limited (FSPKF) is schdueled to report earning on Dec 02, 2026, After Close (Confirmed).
What is Fisher & Paykel Healthcare Corporation Limited (FSPKF) earnings time?
Fisher & Paykel Healthcare Corporation Limited (FSPKF) earnings time is at Dec 02, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FSPKF EPS forecast?
FSPKF EPS forecast for the fiscal quarter 2027 (Q2) is 0.24.